Age-Race Subgroup Compared With Renin Profile as Predictors of Blood Pressure Response to Antihypertensive Therapy
|
|
- Edwin Chapman
- 5 years ago
- Views:
Transcription
1 Clinical Cardiology Age-Race Subgroup Compared With Renin Profile as Predictors of Blood Pressure Response to Antihypertensive Therapy Richard A. Preston, MD, MBA; Barry J. Materson, MD, MBA; Domenic J. Reda, MS; David W. Williams, MS; Robert J. Hamburger, MD; William C. Cushman, MD; Robert J. Anderson, PhD; for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents Context. Renin profiling and age-race subgroup may help select single-drug therapy for stage 1 and stage 2 hypertension. Objective. To compare the plasma renin profiling and age-race subgroup methods as predictors of response to single-drug therapy in men with stage 1 and 2 hypertension as defined by the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Design. The Veterans Affairs Cooperative Study on Single-Drug Therapy of Hypertension, a randomized controlled trial. Setting. Fifteen Veterans Affairs hypertension centers. Patients. A total of 1105 ambulatory men with entry diastolic blood pressure (DBP) of 95 to 109 mm Hg, of whom 1031 had valid plasma and urine samples for renin profiling. Interventions. Randomization to 1 of 6 antihypertensive drugs: hydrochlorothiazide, atenolol, captopril, clonidine, diltiazem (sustained release), or prazosin. Main Outcome Measure. Treatment response as assessed by percentage achieving goal DBP ( 90 mm Hg) in response to a single drug that corresponded to patients renin profile vs a single drug that corresponded to patients age-race subgroup. Results. Clonidine and diltiazem had consistent response rates regardless of renin profile (76%, 67%, and 80% for low, medium, and high renin, respectively, for clonidine and 83%, 82%, and 83%, respectively, for diltiazem for patients with baseline DBP of ). Hydrochlorothiazide and prazosin were best in lowand medium-renin profiles; captopril was best in medium- and high-renin profiles (low-, medium-, and high-renin response rates were 82%, 78%, and 14%, respectively, for hydrochlorothiazide; 88%, 67%, and 40%, respectively, for prazosin; and 51%, 83%, and 100%, respectively, for captopril for patients with baseline DBP of ). Response rates for patients with baseline DBP of 95 to 99 mm Hg by age-race subgroup ranged from 70% for clonidine to 90% for prazosin for younger black men, from 50% for captopril to 97% for diltiazem for older black men, from 70% for hydrochlorothiazide to 92% for atenolol for younger white men, and from 84% for hydrochlorothiazide to 95% for diltiazem for older white men. Patients with a correct treatment for their renin profile but incorrect for age-race subgroup had a response rate of 58.7%; patients with an incorrect treatment for their renin profile but correct for age-race subgroup had a response rate of 63.1% (P =.30). After controlling for DBP and interactions with treatment group, age-race subgroup (P.001) significantly predicted response to single-drug therapy, whereas renin profile was of borderline significance (P =.05). Conclusions. In these men with stage 1 and stage 2 hypertension, therapeutic responses were consistent with baseline renin profile, but age-race subgroup was a better predictor of response. JAMA. 1998;280: AMONG the more controversial issues in the practice of medicine is thechoiceof an initial antihypertensive agent in patients with stage 1 and stage 2 hypertension. 1-3 Inthegeneralpopulation,67% of hypertensive patients have stage 1 hypertension (diastolic blood pressure [DBP], mm Hg) and 22% have stage 2 hypertension ( mm Hg). 4 These groups are the most likely to benefit from single-drug therapy. Primary hypertension demonstrates heterogeneity in its response to specific types of drug therapy. Available antihypertensive drug classes elicit widely varying blood pressure responses among equally hypertensive patients. Although this phenomenon is generally recognized among clinicians, it has been addressed by relatively few large clinical trials. While the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI 1 ) recommends a diuretic or -blocker as the first- From the Division of Clinical Pharmacology, Department of Medicine (Dr Preston) and the Department of Medicine (Dr Materson), University of Miami School of Medicine, Miami, Fla; Cooperative Studies Program, Edward Hines Jr Veterans Affairs Hospital, Hines, Ill (Messrs Reda and Williams and Dr Anderson); Renal Section, Veterans Affairs Medical Center, Boston, Mass (Dr Hamburger); and Preventive Medicine Section, Veterans Affairs Medical Center, Memphis, Tenn (Dr Cushman). For a complete list of the members of the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents, see Am J Cardiol. 1996;78: Corresponding author and reprints: Richard A. Preston, MD, MBA, Division of Clinical Pharmacology and Pharmacokinetics and Clinical Research Center, Department of Medicine, University of Miami School of Medicine, 1500 NW 12th Ave, 15th Floor, West Tower, Miami, FL Clinical Cardiology section editors: Bruce Brundage, MD, University of California, Los Angeles School of Medicine; Margaret A. Winker, MD, Senior Editor, JAMA. This article is one of a series sponsored by the American Heart Association JAMA, October 7, 1998 Vol 280, No. 13 Predictors of Blood Pressure Response to Antihypertensive Therapy Preston et al
2 line agent, other antihypertensive medications are suggested for special conditions. Some data suggest that the renin profile is useful for evaluating the pathophysiology of primary hypertension and for planning its treatment The investigators of these studies suggest that the renin-profile model may be used to prospectively choose an initial antihypertensive drug, in addition to screening for secondary causes of hypertension and to estimate cardiovascular risk. These investigators suggest that biochemical stratification of patients by renin profile provides insight into the mechanisms contributing to hypertension and can be useful in predicting response to a particular antihypertensive drug. For example, diuretic therapy would be most effective in low-renin hypertension and least effective when renin levels are high. 5-6,8-10 Conversely, angiotensin-converting enzyme inhibitors and -adrenergic blockers, which potentially would be effective in patients with high renin levels, are expected to be less effective in low-renin hypertension. Therefore, plasma renin profiles have an important theoretical role in targeting specific antihypertensive therapies for the individual patient and for identifying drugs that may be ineffective. However, this model has not been tested prospectively in large numbers of patients comparing different classes of antihypertensive agents. A second method for selection of an initial antihypertensive agent is by age-racesubgroup. 11,12 Recently,theDepartment of Veterans Affairs Cooperative Study Group on Antihypertensive Agents published a trial of 1292 patients and determined that patients had different responses to different antihypertensive drugs based on their age-race subgroups. Specifically, younger black men responded best to diltiazem and atenolol, younger white men responded best to captopril and atenolol, older black men responded best to diltiazem or hydrochlorothiazide, and older white men responded best to atenolol or diltiazem. 11,12 To determine whether renin profiling or age-race subgroup identifies which antihypertensive drug is most likely to be effective as a single agent, we analyzed data from the Veterans Affairs Cooperative Study The objectives of this study were as follows: (1) to determine the response rates to each of 6 classes of antihypertensive agents based on renin profile and baseline DBP in a large study population, (2) to determine whether patients would respond to drugs in a manner compatible with that predicted by the renin-profile model for selecting an antihypertensive drug, and (3) to compare the response rates and changes in systolic blood pressure (SBP) and DBP of the renin-profile method ith the age-race subgroup method of choosing an initial antihypertensive agent in patients with stage 1 and stage 2 hypertension. METHODS Study Design The design of this study has been previously reported. 11,12 At the time of randomization, patients with a DBP of 95 to 109 mm Hg after receiving a placebo for 2 weeks were assigned with equal probability in a double-blind manner to 1 of 7 treatmentgroups:placeboor1of 6study drugs. Randomization was stratified by participating site. The drugs and their 24-hour doses(listed from initial to maximum dose) were hydrochlorothiazide (12.5, 25, and 50 mg daily), atenolol (25, 50, and 100 mg daily), clonidine (0.2, 0.4, and 0.6 mg in divided doses given twice daily), captopril (25, 50, and 100 mg in divided doses given twice daily), prazosin (4, 10, and 20 mg in divided doses given twice daily), and a sustained-release preparation of diltiazem (120, 240, and 360 mg in divided doses given twice daily). Prazosin was started at 1 mg given twice daily for 2 days to minimize the risk of hypotension with the first dose. All medications were started at the lowest dose, and the dose was increased every 2 weeks, as required, until a goal DBP of less than 90 mm Hg was reached without intolerance to the drug on 2 consecutive visits or until the maximal drug dose was reached. The blood pressure during treatment was taken as the mean of the blood pressures recorded during the last 2 visits during the titration phase. The group of patients randomized to placebo was not included in this analysis. We compared response rates (percentageofthoseachievinggoaldbp 90 mm Hg at the end of titration) and respective changes in SBP and DBP on the various drugs according to renin profile and baseline DBP. 5 This model indicates that a patient with a high-renin profile should respond best to either an angiotensin-converting enzyme inhibitor or a -blocker. On the other hand, a patient with a low-renin profile should respond to a thiazide diuretic, an 1 -blocker, or a calcium antagonist. 6 Patients with medium renin levels could receive any of the 6 drugs. We compared values of response rate and change in SBP and DBP for renin profile matched patients with the values obtained for patients receiving drugs that were found by our previous study to have the highest response rates based on age-race subgroup. 11,12 In this model, we selected the best 2 drugs from each age-race subgroup and determined the combined response rates and respective changes in SBP and DBP. The subgroups selected were younger ( 60 years) black patients receiving diltiazem or atenolol, older black patients receiving diltiazem or hydrochlorothiazide, younger white patients receiving captopril or atenolol, and older white patients receiving atenolol or diltiazem. We chose the best 2 drugs in each category because in any particular patient, there may be reasons for not prescribing a particular agent, or there may be adverse effects that result in use of the given drug being discontinued. Accordingly, we allowed for the possibility that the best drug in each category might not be suitable in every case. Renin Profiling Renin profiling was performed during the prerandomization phase while the patient was taking single-blind placebo medication. The patients reported to the hypertension unit by 8 AM and a blood sample for plasma renin activity was collected in a vacuum tube (B-D Vacutainer, Becton Dickinson, Franklin Lakes, NJ) containing potassium-edta at room temperature. The sample was centrifuged at room temperature within 1 hour of collection for 10 to 12 minutes at 1000g to 1200g. The plasma was separated, transferred to a polystyrene test tube (taking care not to include erythrocytes), and quick-frozen in a dry ice acetone or dry ice alcohol mixture. It was then sent to a central laboratory(r.j.h.) on dry ice along with an aliquot of a 24- hour urine specimen that had been collected over the previous 24 hours. Plasma samples that thawed before arrival at the central laboratory were excluded from the analysis. Plasma renin activity was determined by quantifying angiotensin I generated from endogenous substrate using the technique developed by Haber et al 14 as modified for use in our laboratory. 15 A radioimmunoassay kit (Clinical Assays, Gamma Coat 125I Plasma Renin Activity RadioimmunoassayKit,Travenol-GenentechDiagnostics, Cambridge, Mass) was used. Angiotensin I was generated at a ph of 5.5 using EDTA and phenylmethylsulfonylfluoride for inhibition of angiotensinconverting enzyme and angiotensinases. Sample dilution was minimized by using only 0.1 ml of buffer to adjust the ph of 1.0 ml of plasma. A standard generation time of 1.5 hours was used; samples having a plasma renin activity of 0.77 nmol L 1 h 1 (1.0 ng/ml/h) or less were reincubated for a total of 18 hours The coefficients of variation for replicate determination of the same samples used to JAMA, October 7, 1998 Vol 280, No. 13 Predictors of Blood Pressure Response to Antihypertensive Therapy Preston et al 1169
3 standardize the method were 5.6% (n = 24, 4 separate analyses) and of samples within a single assay, 4.7% (n = 12). A standard renin profiling curve was constructed by using normal volunteers who were given 3 test diets: less than 75 mmol/d (low), 75 to 150 mmol/d (medium), and more than 150 mmol of sodium/d (high) with a potassium content of 50 to 80 mmol/d. Patients from the current study were categorized as having low-, medium-, or high-renin essential hypertension if their values fell below, within, or above the 90% confidence limits for this plasma renin activity vs sodium excretion curve Statistical Methods To determine whether the treatment groups were comparable at baseline, we compared mean age, SBP, heart rate, 24-hour urine sodium excretion, and body mass index (a measure of weight in kilograms divided by the square of height in meters) using 1-way analysis of variance (ANOVA). 21 If the ANOVA P value was statistically significant, we used the Tukey test to determine which pairs of treatments were different. 21 We compared race distributions across treatments using the 2 test. If this was statistically significant, we used the Grizzle-Starmer-Koch method to determine which pairs of treatments were different. 22 To compare the renin profile and agerace subgroup methods, we performed a matched pairs analysis. In this analysis, each patient was classified according to whether he was matched or mismatched for each method. A 2 2 table was formed that defined 4 groups: (1) renin matched, age-race subgroup matched; (2) renin matched, age-race subgroup Table 1. Renin Profile by Age-Race Subgroup mismatched; (3) renin mismatched, agerace subgroup matched; and (4) renin mismatched, age-race subgroup mismatched. The statistical comparison essentially evaluated whether group 2 or 3 had a higher response rate, DBP change, or SBP change. For example, if group 2 had a higher response rate than group 3, then the renin-profile method would be considered more accurate than the agerace subgroup method. We used logistic regression analysis to determine whether baseline ageracesubgroup, andreninprofileweresignificant predictors of response. 23 This analysis included evaluation of interactions between age-race subgroup and drug and between renin profile and drug. The SAS system (version 6; SAS Statistical Software, Cary, NC) was used for all statistical analysis. 24 All statistical tests were 2-sided. The criterion for statistical significance was P.05. RESULTS General Characteristics of the Patients Baseline characteristics of the 1105 patients were well balanced across the 6 treatment groups, including 24-hour urinary sodium excretion. 11,12 The mean (SD) age of the 470 younger patients (those 60 years) was 50 (8) years, and for the 635 older patients (those 60 years) it was 66 (4) years. Low Renin Medium Renin High Renin Low Age-Race Medium Age-Race High Age-Race Subgroup N n Renin, % Distribution n Renin, % Distribution n Renin, % Distribution Younger black Older black Younger white Older white Renin Profile by Age and Race Of the 1105 patients randomized to drug therapy, 1031 provided valid plasmaurine pairs for analysis. Of these, 653 (63.3%) were classified as having lowrenin, 232 (22.5%) as having mediumrenin, and 146 (14.2%) as having highrenin profiles. The renin profile by agerace subgroup is shown in Table 1. Response Rates and Blood Pressure Changes The logistic regression analysis determined the most important predictor of response to a single drug to be baseline DBP (P.001). Clonidine and diltiazem had high response rates regardless of renin profile (Table 2). Hydrochlorothiazide and prazosin performed best in patients with low-renin and medium-renin profiles. Captopril performed best in patients with medium-renin and high-renin profiles. As shown in Table 3, clonidine and diltiazem had high response rates regardless of age or race. Hydrochlorothiazide and prazosin produced poorer blood pressure responses in younger white patients, while captopril did worst among older black patients. Using matched pairs analysis, we found no significant differences between the renin profile and age-race subgroup methods for choosing an initial antihypertensive agent with regard to response rate, change in SBP, or change in DBP (Table 4). For the renin-matched, age-race subgroup mismatched patients, the response rate was 58.7% compared with 63.1% for the renin-mismatched, agerace subgroup matched patients (P =.30). For the changes in these groups were 10.7 and 11.5 mm Hg, respectively (P =.28). The SBP changes were 12.9 mm Hg and 10.5 mm Hg, respectively (P =.06). When age-race subgroup and renin profile were considered simultaneously in the logistic regression analysis, agerace subgroup was found to be a better predictor than renin profile (Table 5). The P value for age-race subgroup and its interactions with treatment group addedtoamodelthatonlyincludedbaseline DBP and treatment group was P.001.ThePvalueforreninprofileand its interactions with treatment group addedtoamodelthatincludedonlybaseline DBP and treatment group was.05. In the presence of renin profile, adding age-racesubgrouptothemodelproduced an incremental improvement, whereas Table 2. Response Rate: Percentage of Patients Reaching Goal Diastolic Blood Pressure (DBP) by Renin Subgroup and Baseline DBP* Antihypertensive Drug (n = 408) Low Renin Medium Renin High Renin (n = 245) (n = 151) (n = 81) (n = 100) (n = 46) Hydrochlorothiazide Atenolol Captopril Clonidine Diltiazem Prazosin *Goal DBP was less than 90 mm Hg at the end of the titration period JAMA, October 7, 1998 Vol 280, No. 13 Predictors of Blood Pressure Response to Antihypertensive Therapy Preston et al
4 Table 3. Response Rate: Percentage of Patients Reaching Goal Diastolic Blood Pressure (DBP) by Age-Race Subgroup and Baseline DBP* Antihypertensive Drug (n = 139) Younger Black Older Black Younger White Older White (n = 108) (n = 172) (n = 114) (n = 140) (n = 83) (n = 256) (n = 93) Hydrochlorothiazide Atenolol Captopril Clonidine Diltiazem Prazosin *Goal DBP was less than 90 mm Hg at the end of the titration period. Table 4. Response Rate and Changes in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Using Renin Profile vs Age-Race Subgroup Methods for Choice of an Initial Antihypertensive Agent the converse was not true. When agerace subgroup and its interactions were added to a model that included baseline treatment group, renin profile, and its interactions, the P value for the agerace subgroup component of the model was.001. When renin profile and its interactions were added to a model that included baseline treatment group, and age-race subgroup and its interactions, the P value for the renin-profile component of the model was.14. COMMENT The renin profiles in our study group (Table 1) are consistent with known renin-profile patterns. The black patients Age-Race Subgroup Method Renin Profile Method Correct Incorrect Combined Response Rate, %* Correct Incorrect Combined Change in SBP, mm Hg Correct 13.9 (10.0) 12.9 (11.8) 13.3 (11.1) Incorrect 10.5 (11.7) 11.2 (11.9) 11.0 (11.8) Combined 12.8 (10.6) 12.3 (11.8) Change in mm Hg Correct 13.7 (5.8) 10.7 (6.9) 11.9 (6.6) Incorrect 11.5 (7.0) 10.6 (6.3) 10.8 (6.4) Combined 13.0 (6.2) 10.7 (6.5) *P =.30 for comparison of renin profile method to age-race subgroup method. P =.06 for comparison of renin profile method to age-race subgroup method. Values are mean (SD). P =.28 for comparison of renin profile method to age-race subgroup method. Values are mean (SD). Table 5. Logistic Regression Model for Response by Age-Race Subgroup vs Renin Profile Subgroup* Factors Included in the Model Model 1: Age-Race Model 2: Renin Profile Model 3: Age-Race, Renin Profile Treatment group Baseline DBP Age, race, age*race (and interactions with treatment group) Renin profile (and interactions with treatment group) C-index Concordance rate, % *Values are P values unless otherwise indicated. Ellipses indicate that variable was not included in the model. DBP indicates diastolic blood pressure. Age*race indicates an interaction term. C-index indicates variability explained by the model. Concordance rate indicates concordance between blood pressure response and model including DBP and age-race subgroup (1); DBP and renin profile (2); or age-race subgroup, and renin profile (3). tended toward low-renin profiles while the white patients tended toward medium- and high-renin profiles. More than 70% of black patients had low-renin profiles, compared with less than 55% of whites. The results of response rate by blood pressure stage and by renin subgroup (Table 2) show that patients with stage 1 hypertension had the highest response rates to the individual drugs, but the response rates for the patients with stage 2 hypertension were not trivial. Diltiazem, clonidine, and atenolol had the best observed response rate in the patients with stage 2 hypertension, but this may have been at least in part due to relatively high doses permitted at the last titration step (diltiazem [sustained release], 360 mg; clonidine, 0.6 mg; and atenolol, 100 mg). Captopril had only a 14% observed response rate for stage 2 hypertension, but the maximum dose allowed was only 100 mg. Hydrochlorothiazide was capped at 50 mg, but this probably is a reasonable upper limit. Prazosin was used at its maximum recommended dose, but was less effective for patients with stage 2 hypertension. For patients with stage 1 hypertension and a low-renin profile, prazosin, diltiazem, and hydrochlorothiazide had the highest response rates; clonidine and diltiazem were best for stage 2 hypertension. For patients with stage 1 hypertension and normal-renin profiles, diltiazem, captopril, and hydrochlorothiazide had the highest response rates; diltiazem, clonidine, and hydrochlorothiazide were best for stage 2 hypertension. Patients with stage 1 hypertension and high-renin profiles had the best response from captopril, atenolol, and diltiazem; for stage 2 hypertension, diltiazem, atenolol, and clonidine were best. Clonidine and diltiazem had high response rates for both stage1andstage2hypertensionirrespective of the renin profile. Our comparison of renin profiling and age-race subgroup for selection of an initial antihypertensive drug does not reveal a significant difference between the 2 methods (Table 4). The low response of the group with medium renin levels in the renin-profiling method may be due to the random assignment of the patients with medium renin levels to any of the 6 antihypertensive drugs. Actually, strict application of the renin-profiling method requires performing a captopril test by which additional patients with renindependent hypertension may be identified. Accordingly, we recalculated the overall response rate of the reninprofile patients substituting the higher figure 72.3% for the medium-renin response rate that was found for the patients with high-renin levels randomized to captopril or atenolol rather than the lower figure of 61.6% that was obtained by random assignment. The resulting figure is 68.6% for the renin- JAMA, October 7, 1998 Vol 280, No. 13 Predictors of Blood Pressure Response to Antihypertensive Therapy Preston et al 1171
5 profile method. Nevertheless, we could demonstrate no statistical difference between the 2 methods. When both age-race subgroup and renin profile are considered simultaneously for selection of an antihypertensive drug, age-race subgroup is the more powerful predictor and renin profile has no additional predictive benefit after age-race subgroup is considered. Our study addresses the choice of an initial antihypertensive agent with respect to its efficacy in long-term lowering of blood pressure. We have not addressed References 1. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1997;157: Weber MA, Laragh JH. Hypertension: steps forward and steps backward: the Joint National Committee fifth report. Arch Intern Med. 1993; 153: Tobian L, Brunner HR, Cohn JN, et al. Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V consensus guidelines. Am J Hypertens. 1994;7(pt 1): Hypertension Detection and Follow-up Program Cooperative Group. The Hypertension Detection and Follow-up Program: a progress report. Circ Res. 1977;40(suppl I):I-106 I Laragh JH, Sealey JE. Renin system understanding for analysis and treatment of hypertensive patients: a means to quantify the vasoconstrictor elements, diagnose curable renal and adrenal causes, assess risk of cardiovascular morbidity, and find the best-fit drug regimen. In: Laragh JH, Brenner BM. Hypertension: Pathophysiology, Diagnosis, and Management. New York, NY: Raven Press Ltd; 1995: Blumenfeld JD, Mann SJ, Laragh JH. Clinical evaluation and differential diagnosis of the individual hypertensive patient. In: Laragh JH, Brenner BM. Hypertension: Pathophysiology, Diagnosis, and Management. New York, NY: Raven Press Ltd; 1995: other potential applications of the reninprofiling method such as screening for secondary forms of hypertension or categorization of hypertensive patients in terms of overall cardiovascular risk. Although we did not perform a detailed cost analysis, the implications for cost savings inusingtheage-racemethodvsthereninprofiling method (which requires additional laboratory testing and a 24-hour urine collection) are clear. It is important to note that our study subjects responded according to renin profile, consistent with prior clinical trials and published algorithms. However, classifying patients according to agerace subgroups is as good a predictor of antihypertensive response as renin profiling. We conclude that age-race subgroup is a useful predictor of antihypertensive response to drug therapy. This cost-free method for the selection of an initial single drug for treatment of stage 1 and stage 2 hypertension after consideration of morbidity and mortality trial results and other compelling indications is fully compatible with the recommendations of JNC VI Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of renin/sodium profile with risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324: Laragh JH. Renin profiling for diagnosis, risk assessment, and treatment of hypertension. Kidney Int. 1993;44: Laragh JH. Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). J Hum Hypertens. 1995;9: Laragh JH. The renin system and four lines of hypertension research. Hypertension. 1992;20: Materson BJ, Reda DJ, Cushman WC, et al. Single drug therapy in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328: Materson BJ, Reda DJ. Correction: single-drug therapy for hypertension in men [letter]. N Engl J Med. 1994;330: Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs single-drug therapy of hypertension study: revised figures and new data. Am J Hypertens. 1995;8: Haber E, Koerner T, Page LB. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normalhumansubjects. JClinEndocrinolMetab. 1969; 29: Hamburger RJ, Flamenbaum W. Renin angiotensin axis. In: Breslin DJ, ed. Renovascular Hypertension. Baltimore, Md: Williams & Wilkins; 1982: Sealey JE, Laragh JH. Radioimmunoassay of plasma renin activity. Semin Nucl Med. 1975;5: Sealey JE, Laragh JH. How to do a plasma renin assay. Cardiovasc Med. 1977;2: Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughn ED Jr. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med. 1972;52: Laragh JH. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med. 1973;55: Case DB, Wallace JM, Keim HJ, Weber MA, Sealey JE, Laragh JH. Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. N Engl J Med. 1977;296: Woolson RF. Statistical Methods for the Analysis of Biomedical Data. New York, NY; John Wiley & Sons Inc; Grizzle JE, Starmer CF, Koch GG. Analysis of categorical data by linear models. Biometrics. 1969; 25: HosmerDW,LemeshowS. AppliedLogisticRegression. New York, NY: John Wiley & Sons Inc; SAS Institute Inc. SAS/STAT User s Guide, Version 6. 4th ed. Cary, NC: SAS Institute; JAMA, October 7, 1998 Vol 280, No. 13 Predictors of Blood Pressure Response to Antihypertensive Therapy Preston et al
JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Diuretics and -Blockers Do Not Have Adverse Effects at 1 Year on Plasma Lipid and Lipoprotein Profiles in Men With Hypertension M. Raj Lakshman, PhD; Domenic J. Reda, MS; Barry J.
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationAntihypertensive efficacy of olmesartan compared with other antihypertensive drugs
(2002) 16 (Suppl 2), S24 S28 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh compared with other antihypertensive drugs University Clinic Bonn, Department of Internal
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationhydrochlorothiazide in the treatment of moderate arterial
Br. J. clin. Pharmac. (1987), 23, 65S-69S Determination of the optimal dosage regimen of captopril + hydrochlorothiazide in the treatment of moderate arterial hypertension D. STERU1, M. CHILDS', S. LANCRENON',
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationTarget Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD
Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD Associate Professor, Clinical Pharmacology Corresponding author Waleed M. Sweileh, PhD
More informationOverview of the outcome trials in older patients with isolated systolic hypertension
Journal of Human Hypertension (1999) 13, 859 863 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Overview of the outcome trials in older patients with isolated
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationThe effective treatment of hypertension is surprisingly. Unsolved Problems in Treating Hypertension. Rationale for New Approaches. Michael A.
AJH 1998;11:145S 149S Unsolved Problems in Treating Hypertension Rationale for New Approaches Michael A. Weber Two major problems continue to challenge hypertension experts and clinical practitioners.
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationIndividual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki
Individual management of arterial hypertension Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki From Population to Individual Management of Arterial Hypertension Epidemiologic impact
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationEPLERENONE (INSPRA ) THE FIRST SELECTIVE ALDOSTERONE RECEPTOR ANTAGONIST FOR THE TREATMENT OF HYPERTENSION
Volume 18, Issue 6 March 2003 EPLERENONE (INSPRA ) THE FIRST SELECTIVE ALDOSTERONE RECEPTOR ANTAGONIST FOR THE TREATMENT OF HYPERTENSION Eun-Jeong Kim, Pharm.D. Candidate Introduction Approximately 50
More informationOsama Sanad (MD) Prof. of Cardiology Benha University 2016
Osama Sanad (MD) Prof. of Cardiology Benha University 2016 Back in time. 1912 Back in time. 1912 No body knows that hypertension is a lethal disease Hypertension in 1940s Among anti-hypertensives mentioned
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More information...SELECTED ABSTRACTS...
The following abstracts, from peer-reviewed journals containing literature on vascular compliance and hypertension, were selected for their relevance to this conference and to a managed care perspective.
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION CORPORATION DATE: 17-04-2015, VERSION 2 VI.2 Elements for
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationIn the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationEvolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)
Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina
More informationPrevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patients
Original Paper Prevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patients CME Credit 1 www.lejacq.com/cme John D. Bisognano, MD, PhD; 1 Kevin A. Townsend, MS,
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationDiabetes and Hypertension
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
More informationPhase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018
Phase 3 investigation of aprocitentan for resistant hypertension management Investor Webcast June 2018 The following information contains certain forward-looking statements, relating to the company s business,
More informationThe management of hypertension has become
AJH 1997;10:743 749 Additive Effects of Diltiazem and Lisinopril in the Treatment of Elderly Patients With Mild-to-Moderate Hypertension Paul Chan, Chun-Nan Lin, Brian Tomlinson, Tz-Hsin Lin, and Ying-Shiung
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationWhich antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017
Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent
More informationPreventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex
Prevention and Rehabilitation Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex Nathan D. Wong, PhD, a Gaurav Thakral, BS, a Stanley S. Franklin,
More informationRESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University
RESISTENT HYPERTENSION Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University Resistant Hypertension Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive
More informationRenal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School
Renal Denervation by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School Disclosure Information ACOI Annual Meeting I have the following financial relationships to disclose:
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationThiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14
Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14 Disclosures Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationThe hypertensive effects of the renin-angiotensin
Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring George Bakris, MD A prospective, randomized, open-label, blinded end-point
More informationdoi: /01.CIR
Effect of Single-Drug Therapy on Reduction of Left Atrial Size in Mild to Moderate Hypertension: Comparison of Six Antihypertensive Agents John S. Gottdiener, Domenic J. Reda, David W. Williams, Barry
More informationSTANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
More informationThe antihypertensive and diuretic effects of amiloride and. of its combination with hydrochlorothiazide
The antihypertensive and diuretic effects of amiloride and of its combination with hydrochlorothiazide The hypotensive effect as well as changes in serum electrolytes and uric acid of amiloride (AM) and
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationHypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program
Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationRACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION
RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION DANIEL L. DRIES, M.D., M.P.H., DEREK V. EXNER, M.D., BERNARD J. GERSH,
More informationPreventing the cardiovascular complications of hypertension
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
More informationManaging High Blood Pressure Naturally. Michael A. Smith, MD Life Extension s Healthy Talk Series
Managing High Blood Pressure Naturally Michael A. Smith, MD Life Extension s Healthy Talk Series Part 1 What is Blood Pressure? Blood Pressure Systole Systolic Forward Pressure 110 mmhg 70 mmhg Diastole
More informationThe control of hypertension in the. Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy REPORTS
REPORTS Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy By Richard V. Milani, MD Abstract Elevated blood pressure, particularly systolic blood
More informationFAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION
Br. J. clin. Pharmac. (1982), 14, 187S-19lS BENEFICIAL EFFECTS OF CAPTOPRIL IN LEFT VENTRICULAR FAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION J.P. BOUNHOURE, J.G. KAYANAKIS, J.M. FAUVEL & J. PUEL Departments
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More information47 Hypertension in Elderly
47 Hypertension in Elderly YOU DO NOT HEAL OLD AGE; YOU PROTECT IT; YOU PROMOTE IT; YOU EXTEND IT Sir James Sterling Ross Abstract: The prevalence of hypertension rises with age and the complications secondary
More informationManagement of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University
Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS:
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationAdult Blood Pressure Clinician Guide June 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationHypertension Update Background
Hypertension Update Background Overview Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Management Guideline Comparison
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationImproving Medical Statistics and Interpretation of Clinical Trials
Improving Medical Statistics and Interpretation of Clinical Trials 1 ALLHAT Trial & ALLHAT Meta-Analysis Critique Table of Contents ALLHAT Trial Critique- Overview p 2-4 Critique Of The Flawed Meta-Analysis
More informationHypertension. Penny Mosley MRPharmS
Hypertension Penny Mosley MRPharmS Outline of presentation Introduction to hypertension Physiological control of arterial blood pressure What determines our bp? What determines the heart rate? What determines
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationAn Epidemiological Overview
An Epidemiological Overview Cardiovascular disease (CVD) is the leading cause of death in the U.S. In 2005 CVD accounted for approximately 38 percent of all deaths CVD has been the number one killer in
More informationHypertension Update. Aaron J. Friedberg, MD
Hypertension Update Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Background Diagnosis Management Overview Guideline
More informationHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension
(2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers
More information